Abstract

This study was conducted to evaluate the mechanism by which n-3 PUFA regulated the protein degradation in C2C12 myotubes. Compared with the BSA control, EPA at concentrations from 400 to 600 µM decreased total protein degradation (P < 0.01). However, the total protein degradation was decreased when the concentrations of DHA ranged from 300 µM to 700 µM (P < 0.01). DHA (400 µM, 24 h) more efficiently decreased the IκBα phosphorylation and increased in the IκBα protein level than 400 µM EPA (P < 0.01). Compared with BSA, 400 µM EPA and DHA resulted in a 47% or 68% induction of the NFκB DNA binding activity, respectively (P < 0.01). Meanwhile, 400 µM EPA and DHA resulted in a 1.3-fold and 2.0-fold induction of the PPARγ expression, respectively (P < 0.01). In C2C12 myotubes for PPARγ knockdown, neither 400 µM EPA nor DHA affected the levels of p-IκBα, total IκBα or NFκB DNA binding activity compared with BSA (P > 0.05). Interestingly, EPA and DHA both still decreased the total protein degradation, although PPARγ knockdown attenuated the suppressive effects of EPA and DHA on the total protein degradation (P < 0.01). These results revealed that DHA inhibits protein degradation more efficiently than EPA by regulating the PPARγ/NF-κB pathway in C2C12 myotubes.

Highlights

  • Nuclear factor-kappa B (NFκB) is one of the most important signaling pathways linked to the loss of skeletal muscle mass in normal physiological and pathophysiological conditions [1]

  • These results demonstrated that the inhibitory effect of 400 μM docosahexaenoic acid (DHA) on the NFκB DNA binding activity in C2C12 myotubes was greater than that of 400 μM eicosapentaenoic acid (EPA)

  • Previous studies have found that eicosapentaenoic acid (EPA, C20:5n-3) decreased gene expression of the muscle RING finger 1 (MuRF1), which has been demonstrated to have ubiquitin-ligase activity [13]

Read more

Summary

Introduction

Nuclear factor-kappa B (NFκB) is one of the most important signaling pathways linked to the loss of skeletal muscle mass in normal physiological and pathophysiological conditions [1]. NFκB expresses constitutively and exists in the cytosol as part of a heterotrimeric complex [2] This complex typically comprises the DNA-binding proteins p50 and p65 plus the inhibitory protein IκBα. There is growing evidence suggesting that long chain eicosapentaenoic acid (EPA, C20:5n-3) can inhibit NFκB activation by preventing the degradation of IκBα in skeletal muscle [8, 9]. It was further observed that long chain EPA, but not α-linolenic acid (ALA, C18:3n-3), can inhibit the NFκB activation in C2C12 myotubes by activating transcription factors peroxisome proliferators-activated receptor-γ (PPARγ) [13]. We hypothesized that longer chain docosahexaenoic acid (C22:6n-3) can more efficiently inhibit the protein degradation by regulating PPARγ/NFκB pathway in C2C12 myotubes than EPA

Objectives
Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call